MicroRNAs (miRNAs) have recently received great attention for their regulatory roles in diverse cellular processes and for their contribution to several human pathologies. Modulation of miRNAs in vivo provides beneficial therapeutic strategies for the treatment of many diseases, as evidenced by various preclinical studies. However, specific issues regarding the in vivo use of miRNA inhibitors (antimiRs) such as organ-specific delivery, optimal dosing and formulation of the best chemistry to obtain efficient miRNA inhibition remain to be addressed. Here, we aimed at comparing the in vivo efficacy of different chemistry-based antimiR oligonucleotides to inhibit cardiac expression of miR-199b, a highly promising therapeutic target for the treatment of pressure overloadinduced cardiac dysfunction. For this purpose, four different designs of oligonucleotides to inhibit miR-199b were initially developed. Systemic administration to wildtype mice on three consecutive days was followed by organ harvesting, seven days after the first injection, in order to quantify the dose-dependent changes in miR199b expression levels. When comparing the efficiency of each inhibitor at the highest applied dose we observed that the antagomir was the only inhibitor inducing complete inhibition of miR-199b in the heart. LNA reduced expression in the heart by 50 percent while the Zen-AMO and F/MOE chemistries failed to repress miR-199b expression in the heart at any given dose, in vivo. Further optimization was achieved by subjecting the antagomir and LNA nucleotides to additional chemical modifications. Interestingly, antagomir modification by replacing the cholesterol moiety from the 3′ to the 5′ end of the molecule significantly improved the inhibitory capacity, as reflected by a 75 percent downregulation of miR-199b expression already at a concentration of 5 mg/kg/day. Similar results could be obtained with a LNA-RNA molecule but upon administration of 80 mg/kg/day. These findings show that, from all the chemistries tested by us, an antagomir carrying the cholesterol group at the 5′ end was the most efficient inhibitor of miR-199b in the heart, in vivo. Moreover, our data also emphasize the importance of chemistry optimization and best dose range finding to achieve the greatest efficacy in miRNA inhibition in vivo.
Introduction
MicroRNAs (miRNAs) are a class of small non-coding endogenous RNA molecules that regulate gene expression at the post-transcriptional level [1] . miRNAs are estimated to regulate over 60% of the human genome and therefore, participate in every cellular process [2] [3] [4] [5] [6] [7] . It is currently established that abnormalities in miRNA biology can contribute to diverse pathologies including cancer, neurodegenerative disorders, cardiovascular diseases and impairment of the immune system [8] [9] [10] [11] [12] . Hence, miRNAs have emerged as potential therapeutic targets in many diseases.
The general aim of miRNA-based therapeutics is to restore miRNA expression levels either by increasing the downregulated miRNAs or inhibiting the upregulated miRNAs in a specific disease stage/condition. In this regard, much effort has been directed to the generation of antisense oligonucleotides, either harboring the full or a partial complementary reverse sequence of the mature miRNA (antimiRs) to inhibit endogenous expression levels of a specific miRNA of interest. RNA oligonucleotides display properties that challenge drug development such as susceptibility to degradation by nucleases when introduced into living organisms, difficult cellular uptake and unfavorable pharmacokinetic properties [13, 14] . To overcome these challenges, https://doi.org/10.1016/j.bcp.2018.11.013oligonucleotides must be chemically modified by either changing the ribose backbone, the phosphodiester linkages or the nucleobases [15] . The ribose is mostly modified by replacement of the 2′-hydroxyl by many different groups among which, the most common are 2′-O-methyl (2′OME), 2′-O-(metoxyethyl) (2′MOE) and 2′fluoro (2′F) [16] . These modifications are mainly employed to increase thermal stability of complementary hybridization, induce higher binding affinity, and to increase stability protecting the RNA molecule from nuclease cleavage [17, 18] . Furthermore, to increase oligonucleotide stability in circulation phosphorothioate groups (PS), which exchange a sulfur atom for a non-bridging oxygen in the phosphate backbone, were also introduced into antimiRs [19] . PS linkages, besides preserving the oligonucleotides in circulation also slow down removal by the liver, increasing the time available for uptake into the target tissues [19] . A combined strategy is to use 2′OME-modified nucleic acids linked with PS bonds at both ends of the molecule in order to protect against exonuclease activity, together with a cholesterol group attached to the 3′ end of the molecule to facilitate in vivo delivery [20] . These specifically designed oligonucleotides were first described as 'antagomirs' [20] . Intravenous administration of naked antagomirs has revealed sufficient uptake by target tissues at relatively high doses (80 mg/kg per body weight) [21] . Synthetic 2′ modifications such as 2′MOE and 2′F were shown to further enhance binding affinity and nuclease resistance of antimiRs [22, 23] . Another modification that confers the oligonucleotide high stability against nuclease attack, while providing great target affinity (average Tm of 2.4 C per modification), is to connect 2′-oxygen to the 4′-carbon via a methylene bridge locking the molecule into a 3′ endo sugar conformation and generate a locked nucleic acid (LNA) [24, 25] . It has been reported that LNA-RNA mixmers show increased silencing potency in cell culture when compared to LNA-DNA mixmers [26, 27] . LNA-DNA mixmers consist of a molecule where the middle 10 DNA nucleotides are flanked by 3 nucleotides on each side which are LNA-modified, while the LNA-RNA combination harbors 11 RNA nucleotides, 2′OME capped, with 5 LNA nucleotides distributed over the total sequence. Another type of modification was obtained by linking a novel non-nucleotide N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine group, so-called ZEN, at or near each end of a phosphodiester 2′OME RNA oligonucleotide [26] . This new oligonucleotide design was shown to be potent in inhibiting miRNAs in vitro at low concentrations with high specificity and low toxicity [26] .
As various pre-clinical studies are ongoing to assess the therapeutic potential of miRNA inhibition in cardiovascular disease models, a consideration of optimal chemistry for the cardiovascular system is still warranted. In the clinic, RG-012 (Regulus/Sanofi), an antimir that targets miR-21 for the treatment of Alport syndrome, a genetic kidney disease, has entered Phase II trials [28] . Moreover, an antimir against miR-122 to treat Hepatitis C, Miravirsen (SPC3629, Santaris/Roche) was able to reduce Hepatitis C virus (HCV) RNA levels without viral resistance in Phase II trials [29] [30] [31] [32] . Despite all these promising achievements, issues such as tissue-specific delivery, inhibitory potency of different chemistries, stability, kidney clearance and cellular uptake remain challenging and need to be addressed. We have previously reported that systemic administration of a specific antagomir efficiently silenced miR-199b in the heart for at least three weeks after treatment [33, 34] . Reducing miR-199b expression to minimal levels in the myocardium, not only prevented progression to HF but also reverted pathologic cardiac phenotypes [33, 34] . Here, we aimed at comparing the in vivo efficacy of six different chemistry-based antimiR oligonucleotides to inhibit miR-199b, a promising therapeutic target for the treatment of heart failure (HF) [33, 34] .
Materials and methods

Animals
Adult B6129SF1/J female wildtype mice (Charles River, L'Arbresle, France), 8-10 weeks of age, were used. All protocols were reviewed and approved by the Animal Care and Use Committee of the University of Maastricht and performed according to the rules formulated by Dutch law on care and use of experimental animals.
Antimir administration
We used the following chemically-modified oligonucleotides to specifically inhibit miR-199b: antagomir-199b with a cholesterol group either at the 3′ or 5′ end of the molecule (antagomir-199b-3′ and antagomir-199b-5′, Eurogentec, Belgium), and LNA-DNA-199b, LNA-RNA-199b 2′F/MOE-199b and Zen-AMO-199b, all from Integrated DNA Technologies (IDT, Belgium). Similar to previous work, [20, 33, 35] animals received either vehicle as control (phosphate-buffered saline, PBS, 0.1 ml) or the different oligonucleotides (in 0.1 ml PBS) by intraperitoneal injections on three consecutive days at a dose ranging from 0.05, 0.5, 1, 5, 10, 20, 40 and 80 mg per kg of body weight (mg/Kg BW) per day. 5 animals were included per group. In some instances, the dose was increased up to 160 and 240 mg/Kg/day. Seven days after starting the treatment the animals were sacrificed and tissues were harvested.
RNA isolation and real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. 1 μg of total RNA was applied to either miR-based or mRNA-based reverse transcription. Real-time PCR was performed on a BioRad iCycler (Bio-Rad) using SYBR Green. Transcript quantities were compared using the relative Ct method, where the amount of target normalized to the amount of endogenous control (L7) and relative to the control sample is given by 2 −ΔΔCt .
Primer sequences for all mRNAs quantified are listed in Table 1 . For miRNA real-time PCR, miRNAs were isolated with TRIzol reagent (Invitrogen) and cDNA was generated with the miScript Reverse Transcription Kit (Qiagen). Detected expression levels of 5S rRNA and miR-16 were used to normalize miR-199b expression in all the analyzed samples. For real-time PCR detection of miRNAs and 5S rRNA, Exiqon microRNA primers (Exiqon) and the ExiLENT SYBR green master mix (Exiqon) were used. 
Western blot analysis
SDS PAGE electrophoresis and blotting were performed as previously described [33, 36] . In short, whole tissue or cell lysates were produced in RIPA buffer supplemented wtih PhosSTOP (Roche) and Protease inhibitor cocktail (Roche). Subsequently samples were boiled in 4x Leammli buffer, including 2% β-mercaptoethanol, for 5 min at 95°C. SDS-PAGE and Western blotting were performed using the Mini-PROTEAN 3 system (Bio-Rad). Blotted membranes were blocked in 5% BSA / TBS-Tween. Primary antibody labeling was performed overnight at 4°C. Secondary IgG-horseradish peroxidase (HRP)-conjugated antibodies were applied for 2 h at room temperature. After each antibody incubation, blots were washed for 3 × 10 min in TBS-Tween. Images were generated using Supersignal West Dura Extended Duration ECL Substrate (Pierce) and the LAS-3000 documentation system (FujiFilm Life Science). Stripping was performed with Restore Western blot stripping buffer (Pierce). Outputs were normalized for loading and results are expressed as an n-fold increase over the values of the control group in densitometric arbitrary units. Primary antibodies that were used included rat monoclonal anti-Notch1 (Cell Signaling Technology, 1:1000), rabbit monoclonal anti-Jagged1 (Cell Signaling Technology, 1:1000), rabbit polyclonal anti-Dyrk1A (Santa Cruz, 1:500), mouse monoclonal anti-GSK3b (Abcam, 1:5000), rabbit polyclonal antiGPCR5a (Novus Biologicals, 1:1000), mouse monoclonal anti-MYL6B (ThermoFisher Scientific, 1:500). Secondary antibodies included mouse monoclonal anti-GAPDH (Millipore, 1:10000), polyclonal goat anti-rat IgG-HRP (Cell Signalling Technology, 1:1000), polyclonal rabbit antimouse IgG-HRP (DAKO, 1:5000) and polyclonal swine anti-rabbit IgG-HRP (DAKO, 1:5000).
Statistical analysis
The results are displayed as mean ± standard error of the mean (s.e.m). Statistical analyses were performed using Prism software (GraphPad Software, Inc. San Diego, CA, USA) and consisted of Student's t-test when comparing two experimental groups. Differences were considered significant when p < 0.05.
Results
Design of four different chemically-modified oligonucleotides to inhibit miR-199b expression
To compare the efficacy of different chemistry-based oligonucleotides in inhibiting miRNAs, we initially designed four different antimiR oligonucleotides to inhibit miR-199b in vivo (Fig. 1a, b ). These antisense oligonucleotides comprehend different chemical modifications affecting different compound properties such as stability, cellular uptake, specificity and delivery. In this regard, antagomir harbors a 2′-O-methyl (2′-OMe) backbone linked by phosphodiester and phosphorothioates bonds and is conjugated to a cholesterol group in order to increase cellular uptake [20] . We first tested an antagomir containing the cholesterol group at the 3′ end of the RNA molecule, a 2′F-MOE which combines 2′F-and 2′-MOE-modified oligonucleotides bound via phosphodiester bonds [22, 23] . We also tested a ZEN-modified 2′-OME conjugated to a cholesterol group at the 3′ end of the RNA molecule and the ZEN modifier linked via phosphate linkages to the ribose backbone of the oligonucleotide [26] . Lastly, a locked nucleic acid (LNA) combined with DNA and a full phosphorothioate backbone [25] designed to target bases 2-17 of the 5′ region of the mature miR-199b sequence was also tested.
Efficiency of different chemically-modified oligonucleotides in inhibiting miR-199b expression in vivo
In order to compare the efficiency of the different oligonucleotides in inhibiting miR-199b expression in vivo, we treated animals with different doses of each antimiR, ranging from 0.05 to 80 mg/kg/day, delivered on three consecutive days by intraperitoneal injections (Fig. 2a) . As control, we included a group of animals, which received vehicle (saline) in a similar delivery scheme. Seven days after the first injection, animals were sacrificed and several organs were harvested for further molecular analysis. A dose-dependent decrease in the levels of miR-199b expression in myocardial tissue was observed after treatment with antagomir-199b-3′ and LNA-DNA-199b (Fig. 2b, c) . However, F/ MOE-199b and Zen-AMO-199b, within the dose range applied, did not inhibit miR-199b in the heart, as assessed one week after treatment (Fig. 2d, e) . Antagomir-199b showed effective inhibition already at a relatively low dose (IC 50 = 8.1 mg/kg/day) and completely inhibited miR-199b expression at a dose of 80 mg/kg/day (Fig. 2b) . LNA-DNA199b, on the other hand, displayed an IC 50 of 16.1 mg/kg/day and achieved maximum inhibition at the dose of 80 mg/kg/day, which is the highest treatment dose in our study (Fig. 2c) .
Since Zen-AMO-199b and F/MOE-199b were unable to inhibit miR199b levels in the heart, we questioned whether these antimiR chemistries had a general defect in entering the myocardium and analyzed whether they were able to silence miR-199b in other organs. To investigate this, we first determined the expression profile of miR-199b in organs such as liver, kidney and lung. Among these, the lung displayed the highest miR-199b expression levels, followed by the heart, kidney and liver (Fig. 3a) . Secondly, we compared the expression levels of miR199b in myocardium, kidney, liver and lung after treatment of animals with each of the different antimiRs at the highest 3 doses (20, 40, 80 mg/kg/day) (Fig. 3b, c) . Both antagomir-199b-3′ and LNA-DNA199b efficiently downregulated miR-199b levels and their inhibitory effect in the lung, kidney and liver was achieved at a lower dose compared to the heart (Fig. 3b, c) . At a dose of 20 mg/kg/day, both antimiRs demonstrated > 75% inhibition of miR-199b (Fig. 3c) . In contrast, Zen-AMO-199b and F/MOE-199b failed to reduce miR-199b expression levels in all of the tested organs tested at the given doses (Fig. 3b, c) . These findings indicate that Zen-AMO and F/MOE oligonucleotides were unable to accumulate in the myocardium and achieve inhibition of their target miRNA, even at the very high dosages tested. This renders the Zen-AMO and F/MOE chemistries unsuitable to achieve cardiac miRNA inhibition in vivo.
Chemistry optimization and maximal efficient dose finding
As our results indicate antagomir and LNA as the most suitable chemical modifications to increase oligonucleotide efficiency in inhibiting cardiac miR-199b in vivo, we next assessed whether further chemical or sequence modifications would further increase their potency. For this purpose, we modified the antagomir by adding the cholesterol group to the 5′ instead of the 3′ end (Fig. 4a ). As the current and well-established solid support phosphoramidite-based synthesis of the oligonucleotides is performed in a 3′-5′ fashion, attaching the cholesterol unit only at the end stage of the synthesis process facilitates purification of the resulting oligonucleotides and increases purity by 10% (from 85.6% to 95.6%). Regarding the LNA oligonucleotides, we changed the sequence to RNA instead of DNA (Fig. 4a) as this was shown to increase their potency in cell culture [27, 37] . Furthermore, we also increased the dose range by including dosages of 160 and 240 mg/kg/day to determine the maximal affect that can be achieved for any of the tested chemistries and to test whether rodents can tolerate these high oligonucleotide concentrations. The results revealed that adding the cholesterol group to the 5′ end substantially increased the potency of the antagomir to inhibit miR-199b expression, as reflected by IC 50 = 1.1 mg/kg/day and a 75% inhibition at 5 mg/kg/day (Fig. 4b, c) . In turn, LNA-RNA was more potent than LNA-DNA by showing a 60% inhibition of miR-199b expression at 20 mg/kg/day, despite a similar IC 50 of 15 mg/kg/day (Fig. 4d) . While for both antagomirs, 100% inhibition was reached at a concentration of 80 mg/kg/ day, we could only achieve 60% inhibition with the LNA-RNA-199b with the high concentrations used. As expected, concentrations such as 160 and 240 mg/Kg/day were toxic and therefore, not well-tolerated by the animals. For all the chemistries tested at 160 and 240 mg/kg/day concentrations, we observed that, in general, the animals showed severe signs of discomfort such as cachexia, increased respiratory rate and lack of physical activity, with increased mortality regardless of the chemistry. All animals that received 240 mg/Kg/day of any antimir died within 2 days after treatment. These data indicate that in general, antimir concentrations above 80 mg/Kg/day induce severe in vivo toxicity.
De-repression of various miR-199b targets
Finally, we analyzed how effective the most potent chemistries were in de-repressing miR-199b target genes. Because the function of a miRNA is determined by its target mRNAs, the pharmacological effect of an antimiR directly relates to re-activation of target genes. To this end, we determined the transcript levels of 6 genes which have been validated [33, 38] or are predicted miR-199b target genes [39] , notch1, jagged1 (Jag1), Dual-specificity tyrosine phosphorylation regulated Kinase 1A (Dyrk1A), Glycogen synthase kinase 3 beta (Gsk3β), G Protein-Coupled Receptor Class C Group 5 Member A (Gprc5A) and Myosin light chain 6B (Myl6b) (Fig. 5a, b) . Since the highest tolerable dose was 80 mg/kg/day for both antagomir-199b-5′ and LNA-RNA-199b, we assessed the expression of target genes at 20, 40 and 80 mg/kg/day. While transcriptional levels of the validated target genes, Jag1 and Dyrk1a, and predicted target Gprc5a were increased upon inhibition of miR-199b with antagomir-199b-5′, treatment with LNA-RNA-199b was only able to de-repress Dyrk1A mRNA levels. Predicted targets such as Notch1, Gsk3b and Myl6b remained unchanged after treatment, regardless of the chemistry of the antimir (Fig. 5a, b) . These data could indicate that binding of miR-199b to the 3′UTR of Notch1, Gprc5a, Gsk3b and Myl6b may result in translational repression or deadenylation of the mRNA, with no changes at the transcript level but only affecting protein levels. However, western blot analysis for all six genes, showed that the observed mRNA levels, after treatment with each of the two chemistries, mostly correlate to the protein levels for each gene, with exception of GPCR5A which did not significantly change in the treated hearts (Fig. 5c, d ). Although these data indicate that both antagomir-199b-5′ and LNA-RNA-199b resulted in de-repression of validated miR-199b target genes, indicating that the antisense oligonucleotides resulted in target engagement, treatment with antagomir199b-5′ successfully de-repressed a higher number of target genes.
Discussion
In this study, we directly compared the potency of four different antimiRs to inhibit miR-199b in vivo and demonstrated that different chemical modifications lead to variations in oligonucleotide inhibitory capacity. LNA and antagomir were the most potent inhibitors among the 4 different antimiRs tested in the different organs but the degree of inhibition in the different organs was highly divergent. While almost complete knockdown of miR-199b was achieved in lung, liver and kidney, antimir efficacy was much lower in the heart reflecting preferential accumulation of antimiRs in kidney and liver [40] . These findings point to the importance of organ-specific delivery of antimiRs in order to avoid undesired side effects outside of the organ/cell of interest.
Unlike previous reports showing higher potency of LNA compared to antagomirs in inhibiting miR-122 in the liver, we have not observed pronounced differences between LNA-DNA and antagomir in their efficiency to antagonize miR-199b at the given dosages, in any of the examined organs [41] . In addition, administration of lower LNA-DNA doses did not repress miR-199b expression levels in the heart in contrast to earlier findings for other miRNAs [42] [43] [44] . These discrepancies suggest that the activity of antimiRs may be dependent on particular characteristics of individual miRNAs such as mature sequence, availability for binding and turnover rate.
A report by Thum et al., demonstrated the variation in potency of different antimiRs to inhibit miR-21 in the heart [45] . By comparing the efficacy of three antimiRs; cholesterol-conjugated antimiR, F/MOE and LNA, either 2 or 19 days after systemic administration, they could conclude that cholesterol-conjugated antimiR and F/MOE have stronger long-term inhibitory effects compared to LNA-DNA. While the long-term inefficiency of LNA may be related to its small size (8 nucleotide in length whereas other antimirs are 22 nucleotide-long), these findings are in agreement with ours in that a miRNA may display different inhibition patterns when targeted by different antimiR oligonucleotides.
Although LNA and antagomir are widely applied antimiRs in most preclinical studies, in the present study, two other relatively new antimiR modifications namely F/MOE and Zen-AMO were also evaluated for their potency in vivo. Zen-AMO has been generated by insertion of a novel non-nucleotide compound named 'Zen' via phosphorothioate (PS) linkages to the 2′OMe RNA backbone [26] . This modification was shown to increase binding affinity and prevent exonuclease degradation in vitro [26] . On the other hand, PS modifications of Zen-AMOs lowers binding affinity and subsequently potency unless short antisense oligonucleotides (such as 12-14mers) are used that can penetrate tissues and enter cells with higher efficiency than longer antimiRs [46] . This may be the explanation for the observed ineffectiveness of Zen-AMO to inhibit miR-199b, as we employed the fulllength (23 nucleotide) oligonucleotide administered without any delivery vehicle, which could have increased the potency. Although this problem was overcome for the antagomirs after conjugation with cholesterol, it seems that even after cholesterol conjugation, Zen-AMO delivery and efficiency in the heart is still impaired. Therefore, further studies are required to explain possible causes driving the impotency of the Zen-AMO used in this study. Up to date, the efficacy of Zen-AMO was analyzed only in cell cultures [47] and so the present study is the first to assess the potency of this antimiR in vivo.
In contrast to Zen-AMO, in vivo efficacy of F/MOE has been verified in several preclinical disease models. Swarbrick et al. achieved sufficient downregulation of miR-380-5p in tumors from an orthotopic mouse model of neuroblastoma after intraperitoneal injection of a specific F/MOE, twice weekly for three weeks, and the treatment resulting in reduced tumour size and weight [48] . Later, Rayner et al. [49] demonstrated that F/MOE-induced inhibition of miR-33a/b in a low-density lipoprotein (LDL) receptor-deficient mouse with established atherosclerotic plaques resulted in increased plasma high-density lipoprotein (HDL) levels and regression of atherosclerosis providing a promising treatment strategy [49] . In fact, this group was the first to show the potency of F/MOE to specifically inhibit miR-33a/b in the liver of non-human primates [50] . It is important to note that these therapeutic effects were obtained at low doses of F/MOE (5-25 mg/kg/ day). However, and since the position of 2′F and 2′MOE modifications in the final oligonucleotide can affect potency, due to lack of detailed information regarding the chemical modifications used in the study by Rayner et al. [50] , we cannot really compare their study with ours. The fact that we did not observe an effect after administration of either F/ MOE or Zen-AMO cannot be attributed to their mechanism of action. F/ MOE sequesters target miRNA in a heteroduplex in a similar manner as LNA [51, 52] and Zen-AMO most likely leads to degradation of the target miRNA as it shares a similar chemical modification as an antagomir (except for the Zen modifier) [20, 53] . In this study F/MOE and Zen-AMO did not efficiently inhibit miR-199b in vivo and, although there is one report showing the efficiency of F/MOE (10 and 80 mg/kg/ day) to inhibit miR-21 in the heart [45] , further studies to explain the pharmacokinetic properties of F/MOE and the discrepancies observed with our study are still necessary.
Although our results indicate antagomir and LNA as the most potent oligonucleotide chemical modifications to inhibit miR-199b in vivo, we were able to further increase their inhibitory efficiency by changing the position of the cholesterol group on the antagomir, and by changing the DNA component of the LNA into RNA, respectively. By merely changing the position of the cholesterol unit from 3′ to the 5′ end of the oligonucleotide sequence, we were able to achieve a 4-to 5-fold increase in miR-199b silencing. Since the pharmacokinetic properties are known to be strongly depended on the ability of the oligonucleotide to bind to and release from the plasma proteins [54] , this might result in the pronounced effect. In fact, conjugation of cholesterol to phosphorothioate oligonucleotides is known to increase their plasma life-time and although 60 min after injection, the levels of 3′-cholesterol conjugates were shown to be 3.8 times higher than those of unconjugated nucleotides, the levels of 5′ conjugates have been shown to be 7.8 times higher [55] .
The efficiency of antimiR treatment on miRNA inhibition can be determined by multiple approaches. Although changes in target gene expression can occur at both mRNA and protein level, the majority occurs due to mRNA destabilization [56] . In this study, the initial readout was the direct change in miRNA expression levels determined by real-time quantitative PCR (QPCR). When directly assessing miRNA expression levels, one must consider that in some instances technical burdens may lead to data misinterpretation as excessive amounts of antimiR can interfere with primer annealing or extension during realtime PCR or the antimiR may be released from subcellular compartments during RNA isolation, which in turn, may result in binding of antimiR to the target miRNA during sample preparation [57] . Moreover, the average level of target regulation is mostly humble and ranges between 20 and 50% change in mRNA which may also hamper determination of significant changes above baseline [58, 59] . Taking these aspects into consideration, we further confirmed the potency of antagomir and LNA to repress miR-199b, at a dose of 80 mg/kg/day, by assessing de-repression of validated target mRNAs by QPCR. Highthroughput data supports that increased miRNA levels result in decreased expression levels of many target mRNAs, with a positive correlation existing between mRNA and protein levels after miRNA repression [58, [60] [61] [62] [63] . We have previously reported Dyrk1a as a directed target gene of miR-199b, responsible for balancing the activation of the Calcineurin-NFAT signaling pathway, mainly by being involved in maintaining baseline levels of nuclear NFAT [33] . Once upregulated, miR-199b inhibits the expression of Dyrk1A which in turn will no longer be available to rephosphorylate NFAT. By shutting down a direct antagonist of NFAT activity, upregulation of miR-199b results in more NFAT being shuttled to the nucleus to induce expression of many genes involved in the pathologic cardiac remodeling response [33] . Furthermore, in a previous study where we subjected mice to myocardial infarction, we have also shown that genes such as notch1 and jagged 1 were derepressed when treating the animals with antagomir-199b [34] . This is confirmed by our data, as the genes that revealed lower mRNA expression after antimir treatment also displayed lower protein levels, Fig. 3 . Antagomir-199b and LNA-199b treatment resulted in efficient silencing of miR-199b in the kidney, lung and liver compared to heart. (a) Real-time PCR analysis of miR-199b expression in liver, kidney, heart and lung. Rnu6-2 was used as a reference gene for normalization. Expression levels in other organs are calculated relative to liver. Dose response expression levels of miR-199b after treatment with antagomir-199b-3′, LNA-DNA-199b, F/MOE-199b and Zen-AMO-199b in (b) the heart, (c) kidney, (d) liver and (e) lung. n = 3-4, *P < 0.05 (mean ± s.e.m.).
independently of the chemistry tested. Jagged 1 was previously established as a direct target gene of miR-199b through which miR-199b can directly affect notch signaling [38] . Downregulation of these targets were again confirmed in the current study, both at the mRNA as well as at the protein levels. An exception was GPCR5a which after antagomir199b-5′ treatment showed reduced mRNA expression but no changes at the protein level, suggesting that for this protein, a mild increase in mRNA expression is not sufficient to observe a significant upregulation at the protein level in the timeframe of the experiment, as a result of different levels of regulation between transcript and protein product and/or protein half live [64] [65] [66] . Although it applies for all the genes analyzed, one cannot neglect the limitations of the techniques used to detect mRNA and protein levels which could also limit precision in the results obtained.
While the choice of antimiR design is dependent on the experimental goal, we point out the importance of organ-specific delivery as well as the characteristics of the miRNA of interest to achieve optimal knockdown after antimiR administration. We have previously observed that three consecutive day injections of 80 mg/Kg/day results in > 80% reduction in expression of several miRs in the heart [33, 35, 36] , an effect that remains for at least 3 weeks after treatment. In those studies, we silenced miRNAs in the context of assessing their effects on cardiac remodeling when achieving maximum silencing in the myocardial tissue. Here, we compared the silencing efficiency of different antimir chemistries in myocardial tissue, regardless of the effects on the cardiac phenotype, since no adverse effects related to miR-199b inhibition were expected, as previously shown by us [33, 34] . But it remains crucial to comprehensively assess antimiR efficacy by combining analysis of miRNA expression levels with detection of mRNA or protein levels of target genes and therapeutic effects in relevant animal models. While issues regarding target specificity, toxicity and pharmacokinetics should receive special attention when using antimiRs in vivo, we did not address them in the present study. Although the studied chemical modifications were designed and generated to enhance cellular uptake of miRNAs, they do not account for cell or organ specificity. To circumvent specificity issues, precise drug delivery systems, including liposomes, polymeric vesicles, polymeric nanoparticles, polymeric micelles and dendrimers, have been investigated for targeted delivery of drugs [67] . Target drug delivery, by aiding in modulating drug pharmacokinetics and avoiding or reducing drug toxicity in non-target cells, has been pursued for cardiovascular disease but with limited solid in vivo data so far, especially when concerning delivery of antimirs opposed to miR mimics. Recently, in vivo applications to overexpress and deliver miRNAs have received much attention but remain a challenge for the field as the use of miRNA mimics is limited by their intolerance to extensive modifications [68] . Nevertheless, recombinant adeno-associated virus vectors have developed as an alternative and promising delivery system [69, 70] , even if it significantly limits any therapeutic approach that requires short-term and/or interval drug administration.
While from a sterics point of view, the range of possible functional modifications to introduce in antimiRs is restricted, this could be overcome by nanoparticle delivery systems which, in turn, are well suited to support a multitude of delivery-enhancing modifications. Application of such delivery methods was shown to efficiently deliver antimiR-122 to the liver [71] and antimir-155 specifically to tumors [72] . Furthermore, nanoparticles are safe, biodegradable, and successfully in enhancing the delivery of therapeutic agents. In fact, Liu and colleagues were able to deliver miR-21 mimics in swine hearts by using ultra-sound sensitive microbubbles and without inducing cardiac damage [73] . More recently, the use of negatively charged calcium phosphate nanocarriers efficiently delivered miRNAs to the myocardium [74] , even when inhaled by large animal models of cardiac disease [75] .
The strategies described above aid in increasing cell-and organspecific delivery of antimirs and/or miR mimics but they do not address the problem of miR off-target repression which is potentially detrimental by inducing unwanted toxicity and phenotypes. Current approaches of in vivo delivery of antimirs apply high dose of nucleic acids (30-80 mg/Kg), which will penetrate most tissues, with possible exception of the brain [20] . While such strategies can probably be applied in disease conditions where tissue-specific miRNAs are targeted, this will be more challenging when targeting ubiquitously expressed miRNAs. Moreover, in vivo administration of antimiRs has the potential to interfere with immune cell activation and function as they preferentially accumulate in the macrophages from the bone marrow, spleen, and liver [76, 77] . Our study, by optimizing antimir chemistry and performing extensive dose range response, allows for severe reduction in antimir dose, therefore reducing the potential of extreme offtarget effects. Although in our previous studies we have not observed pathological phenotypes in the lungs or kidneys nor the animals displayed signs of discomfort associated with relatively high dose of antagomir [33, 34] , we have not extensively assessed the off-target effects of silencing miR-199b in other organs besides the heart. Furthermore, as the animals were followed for six weeks after treatment [33, 34] , we can only speculate over any adverse effects beyond this timeframe. Nevertheless, optimization of chemistry still should be combined with specific drug-delivery systems as well as with extensive gene targeting profiling to better foresee and understand any unwanted phenotypes.
In conclusion, out of the antimiRs tested here, LNA and antagomir were the most potent inhibitors of miR-199b in heart, liver, lung and kidney whereas administration of F/MOE and Zen-AMO did not repress miR-199b levels in those organs. The reason of F/MOE and Zen-AMO inefficiency remains to be explained in future studies. For the antagomir, placing the cholesterol on the 5′ end resulted in a significant impact in inhibitory efficiency, suggesting increased potency and/or improved delivery. Such result is important when developing optimal therapy for the heart and supports further pursuing miRNAs as novel therapeutic targets and antimir-based therapies for the treatment of heart failure.
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